THE LIFE SCIENCES REPORT 7/11/2014 RXII
NEWS 7/11/ 2014 RXi Pharmaceuticals Corp.
TICKER: RXII:NASDAQ
RXi Pharmaceuticals Corp. is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their … read more
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Comments:
The Life Sciences Report Interview with Reni Benjamin (7/11/14) "RXi Pharmaceuticals Corp. is one of several companies using RNA interference (RNAi) as a platform, and trying to develop therapies for indications not being addressed by competitors. . .RXi is relatively new in this space. It is targeting the processes involved in scarring and fibrosis. We feel the company has largely been ignored by investors, but has potential. . .RXi has Phase 2a data coming out in Q3/14 that would validate its platform, its agent RXI-109, and its gene target CTGF (which expresses the protein connective tissue growth factor [CTGF]).
Scarring is a multibillion-dollar market, primarily in the hypertrophic scarring and keloid areas. . .The initial RXi data should give us enough information to ascertain whether the product can move forward, and whether or not RXi could be a potential acquisition target. These data, if positive, should lead to some significant valuation increase BILIONS. ." More >
Edward White, Laidlaw & Company (6/12/14) "We are initiating coverage on RXi Pharmaceuticals Corp. with a Buy rating and a price target of $9. We believe that the company's innovative RNAi-targeted technologies can address large markets that can potentially generate substantial revenues."
Reni Benjamin, H.C. Wainwright & Co. (5/16/14) "We are reiterating our Buy rating of RXi Pharmaceuticals Corp. and a target price of $9. . .with a strong proprietary platform technology focused on anti-scarring and ophthalmologic applications, a derisked lead asset with the potential to enter multiple therapeutic areas and a cash position of $14M (pro forma), we believe the company represents an undervalued player with significant upside for the long-term investor."
Reni Benjamin, H.C. Wainwright & Co. (5/5/14) "We are initiating coverage of RXi Pharmaceuticals Corp. with a Buy rating and a target price of $9. . .with a strong proprietary platform technology focused on areas of unmet medical need, a derisked lead asset with the potential to enter multiple therapeutic areas and a cash position of $14M (pro forma), we believe the company represents an undervalued player with significant upside for the long-term investor."
The Life Sciences Report Interview with Keith Markey (4/10/14) "RXi Pharmaceuticals Corp. has some very important valuation-driving events in progress, including a couple of clinical trials currently underway. One is for use of its connective tissue growth factor (CTGF) gene-targeting agent, RXI-109. . .a small-interfering RNA (siRNA) molecule being tested as an adjunct to plastic surgery of the lower abdomen for scar revision. . .[the] patients are women who have had a hysterectomy or Cesarean section or abdominoplasty surgery that left a transverse scar of 11 cm in length or more. The other application [involves] surgical revision of keloids, another type of hypertrophic scar. . .
TLSR: These trials are designed so that each patient acts as her own control, with half the hypertrophic scar injected in the abdominal scar revision field, or just one ear injected in the case of a keloid excision. It's a sure way of eliminating age and genetic factors in a patient population and getting a true read on the efficacy of the drug. Was this design a top-management decision?
KM: Yes, it was. . .another smart decision will eliminate a drug-delivery problem we normally see with siRNA molecules when they are used systemically. . .RXI-109 is injected locally and visibly into the scar revision field exactly where you want it to act. . .this particular approach eliminates that delivery issue entirely. . . More >
BIG FARMA acquisition COMING VERY SOON .................
